ADC Therapeutics falls on pausing enrollment for cancer therapy study

ADC Therapeutics SA

11/07/2023 12:35

** Shares of Swiss-based cancer drug developer ADC
Therapeutics SA  ADCT.N  fall 11.8% to $2.09 premarket  
    ** Co says it has paused enrollment of new patients in a
mid-stage study evaluating its drug Zynlonta in combination with
rituximab for treating a type of blood cancer, citing safety
concerns  
    ** Says the Data Monitoring Committee (DMC) signaled
potentially excessive respiratory-related events in patients
with previously untreated diffuse large B-cell lymphoma (DLBCL),
a cancer that starts in the white blood cells  
    ** The treatment resulted in adverse events including seven
fatal events, six of which were individually assessed as
unlikely or unrelated to study drug, company says  
    ** Company says it does not expect to report additional data
from the trial by the end of the year
    ** Up to last close, stock down ~38% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))